Please login to the form below

Not currently logged in
Email:
Password:

generics

This page shows the latest generics news and features for those working in and with pharma, biotech and healthcare.

Novartis’ Mayzent and Roche’s Polivy lead CHMP recommendations

Novartis’ Mayzent and Roche’s Polivy lead CHMP recommendations

The CHMP also recommended marketing authorisations for two generic medicines – Mylan’s Clopidogrel/Acetylsalicylic acid Mylan (clopidogrel/acetylsalicylic acid) for the secondary prevention of atherothrombotic events and Accord’s

Latest news

  • Sandoz expands into Japan with €400m Aspen deal Sandoz expands into Japan with €400m Aspen deal

    Sandoz, the generics division of Swiss pharma Novartis, has agreed to acquire South Africa-based Aspen’s Japanese operations and associated assets to bolster its global presence. . ... The acquisition of Aspen’s Japanese operations would

  • Teva names new CFO and bulks up its opioid liability fund Teva names new CFO and bulks up its opioid liability fund

    Teva’s third-quarter results were hit once again by weak generic sales and the continuing erosion of multiple sclerosis therapy Copaxone (glatiramer acetate) which has lost patent protection and is ... facing competition from both generics and newer MS

  • AstraZeneca launches $1bn Chinese investment fund AstraZeneca launches $1bn Chinese investment fund

    generic products, over a ten-year period, and has agreed licensing deals for three early-stage cancer drugs with Chinese biotech firms.

  • Sandoz finally wins FDA approval for Neulasta biosimilar Sandoz finally wins FDA approval for Neulasta biosimilar

    The patents on the drug expired in the US in October 2015, and in Europe on August 2017, according to data from the Generics and Biosimilars Initiative (GaBi). ... This includes all biosimilars, biopharmaceutical contract manufacturing and Glatopa sales

  • Pfizer raises forecast following growth of biopharma business Pfizer raises forecast following growth of biopharma business

    On the flip-side, Pfizer reported a decline in revenue for its Upjohn generics business, which was down 26% in the quarter. ... It will also likely see growth following its merger with generics company Mylan, which was announced in July and expected to

More from news
Approximately 80 fully matching, plus 1,774 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 6 fully matching, plus 165 partially matching documents found.

Latest appointments

More from appointments
Approximately 3 fully matching, plus 32 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 49 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Using human insights to push healthcare communications forward
This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...
RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...
RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...

Infographics